New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
June 25, 2014
14:46 EDTMYGN, AZNFDA panel does not back accelerated approval of Astra cancer drug, Reuters says
An FDA advisory panel said existing data do not support accelerated approval of AstraZeneca's (AZN) ovarian cancer drug, olaparib, according to Reuters. Shares of Myriad Genetics (MYGN), which is seeking FDA approval for a companion diagnostic test for olaparib, are off their earlier highs following the headlines about the FDA panel decision. Reference Link
News For AZN;MYGN From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
August 27, 2015
07:51 EDTAZNRoche catching up fast to Bristol-Myers in immuno-oncology, says Jefferies
Subscribe for More Information
August 25, 2015
07:41 EDTMYGNMyriad Genetics upgraded on positive risk/reward at Wells Fargo
Subscribe for More Information
06:22 EDTMYGNMyriad Genetics upgraded to Outperform from Market Perform at Wells Fargo
Subscribe for More Information
August 24, 2015
05:13 EDTAZNAstraZeneca to collaborate with Peregrine on cancer immunotherapy clinical trial
Subscribe for More Information
August 23, 2015
12:35 EDTAZNBiotech firms could see 'billions' in sales from new cancer drugs, Barron's says
Subscribe for More Information
August 20, 2015
11:33 EDTAZNLeerink major pharmaceuticals analyst holds an analyst/industry conference call
Subscribe for More Information
09:23 EDTAZNAdvaxis, MedImmune begin enrollment in axalimogene filolisbac Phase I/II study
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.
I agree to the theflyonthewall.com disclaimer & terms of use